Cancer Clinical Trials Results

Cancer Answer Line: 866.223.8100

Cancer Answer Line:

866.223.8100

Cancer Clinical Trials Results

IRBCCTitleHospitalStagePhaseDisease
07-267 Collection of Blood and Tissue from Patients with Upper Aerodigestive Malignancies for Research Purposes (The UAM Tissue Resource)Main Campus  Esophageal, Head & Neck, Lung, Mesothelioma, Thyroid
3164 Cytokine Induced Gene ExpressionMain Campus  Advanced Disease
3952 Analysis of Human Bone Marrow from Donors Undergoing a Bone Marrow HarvestMain Campus  Aplastic Anemia, Bone Cancer, Bone Marrow Failure, Leukemia, Acute Lymphoblastic (ALL) , Leukemia, Acute Myeloid (AML), Leukemia, Chronic Lymphocytic (CLL), Leukemia, Chronic Myeloid (CML), Lymphoma, Hodgkin, Lymphoma, Non - Hodgkin, Multiple Myeloma, Myelodysplastic Syndrome (MDS)
4639 Tissue and Body Fluid Analysis from Renal Cell Cancer PatientsMain Campus  Renal
5024 Collection of Blood & Bone Marrow from Normal Volunteers & Patients for Research Purposes (No Funding)Main Campus  Bone Marrow Failure
7538 Collection of Blood and Bone Marrow Samples of Hematologic Diseases for Research PurposesMain Campus  Multiple Myeloma
ADL 111212-475Automated Systems for Detection and Molecular Characterization of Circulating Tumor CellsMain Campus  Breast
ALEX 1Z1111-245Paroxysmal Hemoglobinuria RegistryMain Campus  PNH
AMGN 1911CC 00164A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered AMG 900 in Adult Subjects with Acute Leukemias and Related DisordersMain Campus Phase 1Leukemia, Acute Lymphoblastic (ALL) , Leukemia, Acute Myeloid (AML)
ARRY 1Z1112-069A Phase I Study of ARRY-614 in Patients with Low or Intermediate-1 Risk Myelodysplastic SyndromesMain Campus Phase 1Myelodysplastic Syndrome (MDS)
ASTX 151212-974A Study of HSP90 Inhibitor AT13387 Alone and in Combination with Crizotinib in the Treatment of Non-small Cell Lung Cancer (NSCLC)Main Campus  Lung
ASTX 181212-1068A Study of HSP90 Inhibitor AT13387 Alone or in Combination with Abiraterone Acetate in the Treatment of Castration-Resistant Prostate Cancer (CRPC) no Longer Responding to AbirateroneMain Campus  Prostate
AVLA 1911CC00171Phase Ib, Escalating Dose Study of AVL-292, a Bruton's Tyrosine Kinase (Btk) Inhibitor, as Monotherapy in Subjects with Relapsed and/or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's MacroglobulinemiaMain Campus Phase 1Leukemia, Chronic Lymphocytic (CLL), Lymphoma, Non - Hodgkin
BAY 151212-1139Phase Ib / II study of BAY 1000394 in combination with cisplatin / etoposide or carboplatin/etoposide as first-line therapy in subjects with extensive disease small cell lung cancerMain Campus Phase 1, Phase 2Lung
BAY 181212-1092Radium-223 Chloride (Alpharadin) in Castration-Resistant (Hormone Refractory) Prostate Cancer Patients with Bone Metastasis trial Main Campus  Prostate
BIP 151212-671A randomized, open-label Phase III trial of afatinib versus erlotinib in patients with advanced squamous cell carcinoma of the lung as second-line therapy following first-line platinum-based chemotherapyMain Campus Phase 3Lung
BNIT 181111-1163A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic, Castrate-Resistant Prostate CancerMain Campus Phase 3Prostate
BRMY 281112-168A Phase 1 Study of BMS-936558 Plus Sunitinib or Pazopanib in Subjects with Metastatic Renal Cell CarcinomaMain Campus Phase 1Renal
BTTC 11-0112-581Randomized, Double-Blind, Placebo-Controlled Trial of Lacosamide for Seizure Prophylaxis in Patients with High-Grade GliomasMain Campus  Brain, High Grade Glioma
CALGB 3090112-645Randomized Phase II Study of Maintenance Pemetrexed versus observation for patients with malignant pleural mesothelioma without progression after first-line chemotherapyBeachwood, Fairview, Hillcrest, Independence, Main Campus, North Coast Cancer, Parma, Strongsville, Wooster Phase 2Mesothelioma
12345678

Cancer Answers & Appointments

Speak with a cancer nurse specialist for appointment assistance and for answers to your questions about cancer locally at 216.444.7923 or toll-free 1.866.223.8100.

Monday through Friday from 8 a.m. – 4:30 p.m. (ET).

Referrals

Resources for medical professionals

  • Outpatient appointment referrals: 216.444.7923 or 866.223.8100
  • Inpatient hospital transfers: 800.553.5056
  • Referring Physician Concierge: 216.444.6196 or 216.312.4910.

Clinical Trials

Search available cancer clinical trials by disease, hospital, phase or number.

This information is provided by Cleveland Clinic and is not intended to replace the medical advice of your doctor or health care provider. Please consult your health care provider for advice about a specific medical condition.

© Copyright 2013 Cleveland Clinic. All rights reserved.